Maze Therapeutics completes HORIZON enrollment, reports Q3 2026 results

Maze Therapeutics said on November 9, 2026 that enrollment for the Phase 2 HORIZON trial evaluating MZE829 in more than 50 patients in a broad AMKD population is complete and exceeded the target enrollment range of 10-15 patients per cohort as previously guided.¹ The company said in early 2027, Maze expects to announce the final data from HORIZON, which is designed to evaluate the potential of MZE829 to treat each of three AMKD patient subgroups: AMKD without diabetes, AMKD with diabetes and AMKD with focal segmental glomerulosclerosis (FSGS).¹ Maze noted that previously reported interim HORIZON data demonstrated clinically meaningful uACR reductions at 12 weeks among 12 efficacy-evaluable AMKD patients¹, according to the company. Subject to regulatory feedback, Maze plans to initiate a pivotal trial in the first half of 2027.¹

On the second pipeline program, enrollment is ongoing in the Phase 2 CIPheR proof-of-concept trial of MZE782 evaluating plasma phenylalanine reduction in PKU, with topline data expected in 2027.¹ Separately, Maze plans to initiate a Phase 2 proof-of-concept trial of MZE782 evaluating proteinuria reduction in CKD in the first half of 2027.¹

In corporate news, Maze announced in August 2026 the appointments of Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., to its Board of Directors, each bringing decades of biopharmaceutical industry and clinical experience.¹

On financials, cash, cash equivalents and marketable securities were $477.0 million as of September 30, 2026, compared to $360.0 million as of December 31, 2025.¹ The company said it expects that its current cash, cash equivalents and marketable securities will fund operations into 2029 based on its current business plan.¹